a Nuclear Medicine , Spedali Civili Brescia , Brescia , Italy.
b Division of Hematology , Spedali Civili , Brescia , Italy.
Leuk Lymphoma. 2019 Feb;60(2):326-333. doi: 10.1080/10428194.2018.1482541. Epub 2018 Jul 3.
Burkitt's lymphoma is a lymphoma with unclear metabolic behavior at 18F-FDG-PET/CT and no validated criteria in treatment evaluation and prediction of outcome exist. Sixty-five patients were retrospectively included: all underwent baseline 18F-FDG-PET/CT, 56 interim PET/CT (iPET/CT) and 54 end of treatment PET/CT (eotPET/CT) after chemotherapy. Interim and eotPET/CT results were visually interpreted according to the criteria of the IHP and Deauville-five-point-scale. Results were correlated with PFS and OS to assess and to compare the predictive value of iPET and eotPET according to each criterion. All baseline PET/CT showed increased 18F-FDG uptake in nodal and extranodal lesions. The median PFS and OS were 44.6 and 48.2 months with 3-year and 5-year PFS of 76% and 62% and 3-year and 5-year OS of 71% and 57%, respectively. EotPET/CT results using DC and IHP significantly correlate with OS and PFS; while iPET/CT did not correlated with OS and PFS.
伯基特淋巴瘤在 18F-FDG-PET/CT 上表现为代谢行为不明确,且在治疗评估和预后预测方面尚无经过验证的标准。本研究回顾性纳入 65 例患者:所有患者均接受基线 18F-FDG-PET/CT、56 次中期 PET/CT(iPET/CT)和 54 次治疗后 PET/CT(eotPET/CT)检查。根据 IHP 和 Deauville 五分制标准,对中期和治疗后 PET/CT 结果进行视觉解读。将结果与 PFS 和 OS 相关联,以评估和比较根据每个标准的 iPET 和 eotPET 的预测价值。所有基线 PET/CT 均显示淋巴结和结外病变的 18F-FDG 摄取增加。中位 PFS 和 OS 分别为 44.6 和 48.2 个月,3 年和 5 年 PFS 分别为 76%和 62%,3 年和 5 年 OS 分别为 71%和 57%。使用 DC 和 IHP 的 eotPET/CT 结果与 OS 和 PFS 显著相关;而 iPET/CT 与 OS 和 PFS 不相关。